vincamine has been researched along with Alloxan Diabetes in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, YJ; Ling, Y; Shen, X; Wang, JY; Wang, YC; Xu, JW; Xu, X; Yang, JZ | 1 |
| Chen, J; Du, T; Hu, L; Huang, X; Lu, J; Lv, J; Shen, X; Shi, X; Wang, H; Xu, X; Yang, L; Ye, J | 1 |
| Naik, PR; Nandini, HS | 1 |
3 other study(ies) available for vincamine and Alloxan Diabetes
| Article | Year |
|---|---|
Vincamine as an agonist of G-protein-coupled receptor 40 effectively ameliorates diabetic peripheral neuropathy in mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Indole Alkaloids; Mice; Monoterpenes; Receptors, G-Protein-Coupled; Sciatic Nerve; Signal Transduction; Vincamine | 2023 |
Vincamine as a GPR40 agonist improves glucose homeostasis in type 2 diabetic mice.
Topics: Animals; Blood Glucose; Cell Line, Tumor; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Homeostasis; Insulin Secretion; Insulin-Secreting Cells; Male; Mice; Receptors, G-Protein-Coupled; Signal Transduction; Vasodilator Agents; Vincamine | 2019 |
Antidiabetic, antihyperlipidemic and antioxidant effect of Vincamine, in streptozotocin-induced diabetic rats.
Topics: Animals; Antioxidants; Blood Glucose; Catalase; Diabetes Mellitus, Experimental; Glutathione; Glycated Hemoglobin; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Kidney; Lipids; Liver; Rats, Wistar; Superoxide Dismutase; Vincamine | 2019 |